Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib study of durvalumab (MEDI 4736) in combination with anti-CD19 CAR transduced T cells in patients with patients with non-Hodgkin's lymphoma

Next Previous
Trial Profile

Phase Ib study of durvalumab (MEDI 4736) in combination with anti-CD19 CAR transduced T cells in patients with patients with non-Hodgkin's lymphoma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; JCAR 014 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors AstraZeneca; Juno Therapeutics; MedImmune

Most Recent Events

  • 28 Apr 2015 New trial record
  • 23 Apr 2015 MedImmune and Juno Therapeutics have announced an immuno-oncology clinical trial collaboration and will jointly co-fund this initial phase Ib study, which is expected to begin in 2015, according to a media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top